Onconova Therapeutics, Inc. — Q1 2018 Form 10-Q
Entity note: The supplied filing is for Onconova Therapeutics, Inc., not Traws Pharma, Inc. The quarter ended March 31, 2018; financial statements are unaudited.
Business context and reporting period
Onconova is a clinical-stage biopharmaceutical company developing oncology treatments, with most current effort focused on rigosertib. Its lead program includes the Phase 3 INSPIRE trial in higher-risk myelodysplastic syndromes (MDS). The company has no recurring source of revenue to fund operations.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Revenue | $564,000 | $210,000 |
| Operating expenses | $6.466 million | $7.002 million |
| Operating loss | $5.902 million | $6.792 million |
| Net loss | $5.090 million | $8.341 million |
| Net loss per share, basic and diluted | $0.34 | $1.23 |
| Cash used in operating activities | $5.509 million | $6.056 million |
| Cash from financing activities | $8.741 million | $40,000 |
- Revenue increased by $354,000, primarily reflecting $450,000 recognized for the HanX license, partly offset by lower clinical-supply revenue from SymBio. The HanX payment was received April 11, after quarter-end, and recorded as a receivable at March 31.
- Net loss narrowed year over year, substantially reflecting the change in fair value of warrant liabilities: an $812,000 gain in Q1 2018 versus a $1.549 million loss in Q1 2017. This is a non-cash valuation item.
- At March 31, cash and cash equivalents were $7.264 million; current assets were $8.555 million and current liabilities $10.552 million, a reported working-capital shortfall of about $2.0 million. Total liabilities were $15.490 million and total stockholders’ deficit was $6.875 million. No separate interest-bearing debt line is shown.
- Management reported an accumulated deficit of $367.406 million and stated there is substantial doubt about the company’s ability to continue as a going concern. It estimated existing cash would fund trials and operations into Q4 2019, but that estimate preceded the subsequent financing described below.
Changes, outlook, risks and unusual items
- General and administrative expense fell 11% to $1.889 million. Research and development expense fell about 6%; management cited lower manufacturing and consulting costs, partly offset by higher clinical and personnel expenses. The statements report R&D of $4.577 million, while the MD&A comparison table gives $4.557 million; the filing text does not provide a clear reconciliation.
- In January 2018, the INSPIRE trial’s independent monitoring committee recommended continuing the study with a planned enrollment expansion from 225 to 360 patients. The company remained blinded to interim results and anticipated topline data in the first half of 2019.
- The company stated that it would not begin the planned Phase 3 oral rigosertib-plus-azacitidine trial, or further development of certain other programs, without additional financing. Hematuria in the oral combination study was reported in 11% of 37 patients using risk-mitigation measures, compared with 48% of 42 patients in the earlier study cohort; the study remained ongoing.
- In February, the company raised approximately $8.7 million net through an offering of common stock and warrants. After quarter-end, the May 1 offering generated approximately $25.6 million net and issued substantial additional common shares and warrants, creating significant potential dilution. The company also reported a Pint equity investment of $1.25 million, which closed April 4.
- The May offering’s Series B preferred shares could not convert until stockholder approval of an increase in authorized common shares. A special meeting was planned for June 7, 2018. The company also reported a Nasdaq minimum-bid-price deficiency, with a stated initial compliance deadline of November 5, 2018; it said the May offering restored compliance with the minimum stockholders’ equity requirement.
- Other developments included a Latin America rigosertib license to Pint, eligible for up to $41.5 million in additional milestones plus royalties, and an NCI collaboration on pediatric cancers associated with RASopathies. These potential payments and programs are contingent and do not represent reported Q1 revenue beyond amounts stated above.
- The company adopted ASC 606 revenue guidance on January 1, 2018, with no material reported effect. Management said disclosure controls were effective and reported no material change in internal control over financial reporting. It reported no pending material legal proceedings.
Important facts for investors to verify
- Confirm the issuer identity: this filing names Onconova Therapeutics, Inc., despite the request metadata naming Traws Pharma, Inc.
- Track INSPIRE enrollment, the expanded 360-patient design, timing of topline results, and any subsequent disclosure of trial outcomes.
- Review the May 2018 financing’s final share and warrant terms, resulting dilution, and the status and outcome of the authorized-share vote.
- Assess cash runway against ongoing operating burn, the stated going-concern doubt, and the company’s dependence on further financing.
- Monitor Nasdaq bid-price compliance and any action needed to maintain listing.
- Reconcile the MD&A R&D expense figure of $4.557 million with the financial-statement figure of $4.577 million.